The FDA Has Granted Orphan Drug Designation To Sage Therapeutics' SAGE-718 For Huntington's Disease
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Orphan Drug Designation to Sage Therapeutics' SAGE-718 for Huntington's Disease. This designation is given to drugs that are intended to treat rare diseases, providing certain benefits to the drug developer.
October 18, 2023 | 10:32 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sage Therapeutics' SAGE-718 has been granted Orphan Drug Designation by the FDA for Huntington's Disease. This could potentially lead to increased attention and investment in the company.
The FDA's Orphan Drug Designation is a significant milestone for any pharmaceutical company as it provides certain benefits such as tax credits, user fee waivers, and eligibility for seven years of market exclusivity upon approval. This could potentially lead to increased attention and investment in Sage Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100